Literature DB >> 19554542

L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure.

Lars Marius Ytrebø1, Rune Gangsøy Kristiansen, Hanne Maehre, Ole Martin Fuskevåg, Trine Kalstad, Arthur Revhaug, María Jover Cobos, Rajiv Jalan, Christopher F Rose.   

Abstract

UNLABELLED: Hyperammonemia is a feature of acute liver failure (ALF), which is associated with increased intracranial pressure (ICP) and brain herniation. We hypothesized that a combination of L-ornithine and phenylacetate (OP) would synergistically reduce toxic levels of ammonia by (1) L-ornithine increasing glutamine production (ammonia removal) through muscle glutamine synthetase and (2) phenylacetate conjugating with the ornithine-derived glutamine to form phenylacetylglutamine, which is excreted into the urine. The aims of this study were to determine the effect of OP on arterial and extracellular brain ammonia concentrations as well as ICP in pigs with ALF (induced by liver devascularization). ALF pigs were treated with OP (L-ornithine 0.07 g/kg/hour intravenously; phenylbutyrate, prodrug for phenylacetate; 0.05 g/kg/hour intraduodenally) for 8 hours following ALF induction. ICP was monitored throughout, and arterial and extracellular brain ammonia were measured along with phenylacetylglutamine in the urine. Compared with ALF + saline pigs, treatment with OP significantly attenuated concentrations of arterial ammonia (589.6 +/- 56.7 versus 365.2 +/- 60.4 mumol/L [mean +/- SEM], P= 0.002) and extracellular brain ammonia (P= 0.01). The ALF-induced increase in ICP was prevented in ALF + OP-treated pigs (18.3 +/- 1.3 mmHg in ALF + saline versus 10.3 +/- 1.1 mmHg in ALF + OP-treated pigs;P= 0.001). The value of ICP significantly correlated with the concentration of extracellular brain ammonia (r(2) = 0.36,P< 0.001). Urine phenylacetylglutamine levels increased to 4.9 +/- 0.6 micromol/L in ALF + OP-treated pigs versus 0.5 +/- 0.04 micromol/L in ALF + saline-treated pigs (P< 0.001).
CONCLUSION: L-Ornithine and phenylacetate act synergistically to successfully attenuate increases in arterial ammonia, which is accompanied by a significant decrease in extracellular brain ammonia and prevention of intracranial hypertension in pigs with ALF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19554542     DOI: 10.1002/hep.22917

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  28 in total

1.  Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia.

Authors:  R Todd Stravitz; Michelle Gottfried; Valerie Durkalski; Robert J Fontana; A James Hanje; David Koch; Bilal Hameed; Daniel Ganger; Ram M Subramanian; Stan Bukofzer; William R Ravis; Kristen Clasen; Averell Sherker; Lanna Little; William M Lee
Journal:  Hepatology       Date:  2018-01-30       Impact factor: 17.425

Review 2.  Management in acute liver failure.

Authors:  Subrat K Acharya
Journal:  J Clin Exp Hepatol       Date:  2014-12-03

Review 3.  Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure.

Authors:  Roger F Butterworth
Journal:  J Clin Exp Hepatol       Date:  2014-07-09

Review 4.  Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.

Authors:  Rune Gangsoy Kristiansen
Journal:  Metab Brain Dis       Date:  2016-09-21       Impact factor: 3.584

5.  Blocking NMDA receptors delays death in rats with acute liver failure by dual protective mechanisms in kidney and brain.

Authors:  Omar Cauli; Alba González-Usano; Andrea Cabrera-Pastor; Carla Gimenez-Garzó; Pilar López-Larrubia; Amparo Ruiz-Sauri; Vicente Hernández-Rabaza; Malgorzata Duszczyk; Michal Malek; Jerzy W Lazarewicz; Arturo Carratalá; Amparo Urios; Alfonso Miguel; Isidro Torregrosa; Carmen Carda; Carmina Montoliu; Vicente Felipo
Journal:  Neuromolecular Med       Date:  2013-12-13       Impact factor: 3.843

6.  (1)H nuclear magnetic resonance spectroscopy-based metabonomic study in patients with cirrhosis and hepatic encephalopathy.

Authors:  Konstantinos John Dabos; John Andrew Parkinson; Ian Howard Sadler; John Nicholas Plevris; Peter Clive Hayes
Journal:  World J Hepatol       Date:  2015-06-28

Review 7.  Ornithine phenylacetate revisited.

Authors:  Maria Jover-Cobos; Lorette Noiret; Yalda Sharifi; Rajiv Jalan
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

8.  Hepatocyte-like cells differentiated from human induced pluripotent stem cells: relevance to cellular therapies.

Authors:  Yue Yu; Hongling Liu; Yasuhiro Ikeda; Bruce P Amiot; Piero Rinaldo; Stephen A Duncan; Scott L Nyberg
Journal:  Stem Cell Res       Date:  2012-06-28       Impact factor: 2.020

9.  Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis.

Authors:  Jasmohan S Bajaj; Vishwadeep Ahluwalia; James B Wade; Arun J Sanyal; Melanie B White; Nicole A Noble; Pamela Monteith; Michael Fuchs; Richard K Sterling; Velimir Luketic; Iliana Bouneva; Richard T Stravitz; Puneet Puri; Kenneth A Kraft; Hochong Gilles; Douglas M Heuman
Journal:  J Hepatol       Date:  2012-08-11       Impact factor: 25.083

10.  Serum-free medium and mesenchymal stromal cells enhance functionality and stabilize integrity of rat hepatocyte spheroids.

Authors:  Ji Bao; James E Fisher; Joseph B Lillegard; William Wang; Bruce Amiot; Yue Yu; Allan B Dietz; Yaakov Nahmias; Scott L Nyberg
Journal:  Cell Transplant       Date:  2012-09-21       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.